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Background:
Access to safe and effective contraception supports the autonomy of women worldwide and is key for promoting individual and public health [1] . When selecting contraceptive methods, women and their providers must weigh the risks and benefits of all available options. Access to the best available evidence on contraceptive safety supports the provision of high-quality family planning care. To assist providers and policymakers with decision-making, the World Health Organization (WHO) publishes the Medical Eligibility Criteria for Contraceptive Use (MEC), an evidence-based guideline document that characterizes the safety of contraceptive methods for women with various medical conditions or personal characteristics [2] .
Providing clarity about the safety of hormonal contraceptive (HC) methods for women at risk of HIV and for women living with HIV is a public health priority. The MEC, which is informed by continuous review of relevant evidence, includes recommendations for use of various contraceptive methods by women at high risk of HIV, women living with HIV, and women using antiretroviral therapy (ART) [2] [3] [4] . Over the past few years, new evidence relevant to intersections between HC and various HIV-related risks prompted WHO to commission updates of two systematic reviews: one on HC method use and HIV acquisition in women [5] , and another on potential drug interactions between HC methods and antiretrovirals (ARVs) [6] .
In December 2016, WHO convened an expert review of available data on HC method use and risk of HIV acquisition in women. At this meeting, the guideline development group reached consensus, and the MEC recommendation for progestogen-only injectable use among women at high risk of HIV changed from a category 1 (meaning that the method can be used without restriction) with a clarification (stating that women should be informed that progestogen-only injectables may or may not increase risk of HIV acquisition) to a category 2 (meaning that advantages of using the method generally outweigh potential risks) with an updated clarification.
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The clarification 1 highlights that women interested in, or using, these methods should be advised of the concern regarding a link between use of these methods and potential increased risk of HIV, about the uncertainty over whether the link is causal, and about how to minimize HIV risk [4] . It is also noted that, provided with full informed consent, women at high risk of HIV infection who still wish to use injectable contraceptives should not be denied access to them.
Since 2015, WHO has convened two other consultations with global stakeholders to discuss the emerging evidence and its implications for research, programmes, and policy -one in adapting the guidance to country-specific contexts, and dissemination and implementation strategies. Importantly, ministry of health representatives discussed development of national responses to account for country-level contextual factors such as HIV prevalence, current contraceptive method mix, and current national family planning programmes.
The major themes that emerged from the 2015 meeting, which were shared and reaffirmed in 2017, will be of interest to researchers seeking to move the body of evidence
forward, to programme planners invested in providing high quality comprehensive sexual and reproductive health (SRH) services for women, and to individuals and groups advocating for SRH rights.
Major themes:
A. Areas for improvement in research methodology and measurement to strengthen future research
A1. Increased inter-disciplinary collaboration and dialogue between basic, clinical, and epidemiological scientists
Several possible biological mechanisms could potentially link use of depot medroxyprogesterone acetate (DMPA) to increased risk of HIV acquisition in women or transmission to men. These include: DMPA influenced structural changes in the female genital epithelium [7] [8] [9] [10] [11] [12] , alterations in cellular targets for infection [8, [13] [14] [15] , alteration of innate and adaptive immune responses [13, [16] [17] [18] [19] [20] , and changes to the female genital tract microbiome [21, 22] . Knowledge and perspective gaps were noted between basic scientists, epidemiologists and clinical scientists. Understanding the complex relationship between HC and HIV will likely require increased collaboration and cross-disciplinary dialogue between these different perspectives.
A2. Enhanced understanding of biological predictors of HIV acquisition:
The lack of identified biological predictors of HIV acquisition is a vital knowledge gap. 
A3. Enhanced understanding of pharmacokinetic findings and potential drug interactions of clinical importance
We identified a lack of data on HC-ART interactions, as well as gaps in translating PK/PD data into clinically useful guidance. Further research is needed to understand how the full range of HC methods interact with a range of ARV regimens [6] . In particular, more research is needed on PK/PD data related to the concurrent use of certain HC methods, including norethisterone enanthate (NET-EN) and long-acting reversible contraceptives (LARCs), with newer ARVs, including integrase inhibitors. Second, it is vital to develop a greater understanding of how outcomes from PK and PD studies (such as changes in exposure to either contraceptive hormones or ARVs due to drug-drug interactions) translate into clinically relevant outcomes for contraceptive effectiveness and ARV safety [6] . Investing in PK/PD studies that follow participants to clinically relevant endpoints may help the research community gain clarity on the meaning of observed PK/PD changes, resulting in individual and public health benefits.
A4. Objective measures of progestin concentrations in blood and relevant tissues, where possible, will improve upon self-reported contraceptive use to inform data
Many studies investigating the relationship between HC method use and HIV have relied on self-reported data collection about HC use, which can introduce misclassification of exposure [23, 24] . Better understandings of systemic and local tissue concentrations of contraceptive 9 hormones associated with typical method use could permit investigators to more accurately categorize contraceptive exposure. Objective measures of progestin levels in blood and relevant tissues (e.g. cervical epithelium) could help avoid exposure misclassification, assist in characterizing differences between progestins, and enhance understanding of how progestin levels in blood and tissues may impact HIV risk.
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A5. Ensuring that future studies appropriately categorize distinct contraceptive formulations, including disaggregating different progestins
Many studies have grouped HC methods together by route of administration, rather than by specific progestin-type; for example, grouping DMPA users with NET-EN users [5] . These progestin-only injectable contraceptive methods are also grouped together in the updated MEC guidance [4] . However, these DMPA and NET-EN are distinct progestins that could differentially impact the risk of HIV acquisition and thus may represent very different exposures [21, 25] . There is a need to characterize differential biological effects on genital epithelium and mucosal immunity, and ultimately, HIV acquisition risk, of the full complement of progestins.
A6. Increased understanding of barriers to diversifying the available contraceptive method mix
Despite the concerns of a potential causal association with increased risk of HIV acquisition in women who use DMPA [4, 5] , this progestin is the most commonly used contraceptive method in many countries with high HIV prevalence [26] . The high prevalence of injectable use in these settings is likely due to a range of structural and systems issues and not to user preference alone [27] . The need to understand why DMPA is so widely used, and how to enhance acceptability and availability of other highly effective contraceptive methods in these settings, was identified as a critical research need. For decades, governments and non-
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10 governmental organizations have made efforts to expand access to a range of contraceptive methods in sub-Saharan Africa [28] [29] [30] [31] [32] . Continuing to expand contraceptive method mix was noted as a key priority, both in 2015 and in 2017. Social science and health services research methods are key for understanding why the method mix in many countries with high HIV prevalence often shows a substantial proportion of DMPA use, and for determining which factors (e.g., provider attitudes, user preferences, government and funder investments, characteristics of health care delivery supply chains) may contribute to high rates of DMPA use in such settings.
A.7. Anticipated advantages and limitations of forthcoming randomized trial results
Observational data, including all currently available studies on HC and HIV acquisition, meetings. WHO serves as a coordinating partner on the ECHO study [33] . Some meeting participants and researchers have expressed concern both about whether the trial will provide clear answers to the question of whether DMPA increases women's risk of HIV, and about the ethics of randomizing women to DMPA [34] [35] [36] [37] [38] . ECHO investigators and other meeting participants, including members of the study's global community advisory boards (who were present at the 2017 meeting), cited that the unresolved relationship between DMPA and HIV
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11 underscores the importance of obtaining randomized trial data to provide clarity on this relationship [39] . It was acknowledged that other questions will remain unanswered, given the limited range of contraceptive options included. Importantly, at the 2017 meeting, country partners were encouraged not to wait for ECHO results to begin implementing countryappropriate policies and programmes in response to the updated MEC guidance on progestogenonly injectables. between HC methods and ARVs should play a role in developing guidance for women exposed to both. The available data on drug interactions should also inform the guidance provided for women using HC methods and PrEP to prevent pregnancy and HIV, respectively.
B2. Integration of woman-centered family planning and HIV services
Findings from implementation research projects that have studied the impact of integrating HIV and family planning services were presented [40, 41] . Integrating HIV and family planning services is a key step that can allow for the provision of high-quality, woman- 
Conclusions and next steps:
WHO and leaders in the research community will continue to monitor the evolving literature and will communicate evidence clearly to stakeholders, advocates, and the public. We hope that the suggested research and programmatic foci presented here will spark conversation and action, to move toward the best ways to collect quality data on the relationship between HIV and HC methods and the best ways to provide high quality, appropriate services for women and men, living with HIV and at risk of HIV acquisition.
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